Licence Agreement with GHFG Ltd.

By

Regulatory News | 19 Jul, 2022

Updated : 07:47

RNS Number : 9454S
Clean Power Hydrogen
19 July 2022
 

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of UK law by virtue of the European Union (withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

 19 July 2022

 

Clean Power Hydrogen Plc

("CPH2", the "Company" or the "Group")

 

Licence Agreement with GHFG Ltd.

 

CPH2, the UK-based green hydrogen technology and manufacturing company that has developed the IP-protected Membrane-Free Electrolyser ("MFE"), is pleased to announce that it has signed its first licence agreement with GHFG Ltd ("GHFG") for the construction of 2 gigawatts ("GW") of MFE electrolysers over a period of up to 20 years.

 

GHFG is a joint venture between international renewable independent power producer, Alternus Energy Group Plc ("Alternus"), and Eric Whelan, CEO of Irish based developer, Soleirtricity. Under the licence agreement, GHFB will produce the CPH2 MFE electrolysers at a new facility in Ireland and plans to start production during 2023. Each electrolyser produced by GHFG under this agreement will be installed alongside and powered from solar energy projects owned and operated by Alternus.

 

Under the agreement, CPH2 will receive an upfront licence fee, and thereafter, a technology fee per unit, followed by service and maintenance licences during the unit's life. The upfront licence fee is expected to be received in full by the end of the current financial year and to be recognised as revenue over the life of the contract.

 

The licensing of the CPH2 proprietary technology offers the Company the potential to significantly increase revenue in the short term without the need for additional capital expenditure. Given the business model's potential low cost and short lead time, the Directors believe it is an ideal opportunity to establish market share and improve market penetration on a global basis by using the high margin, low capex licencing strategy to fund further R&D.

 

CPH2, which is based in Doncaster, has a 2030 production target of 4GW per year, with 1GW made at its own facility and the rest manufactured under license by other companies including GHFG. Through the license, GHFG has access to CPH2's innovative MFE technology whilst having the flexibility to oversee its own production and delivery schedules.

 

 

Jon Duffy, Chief Executive Officer of CPH2, commented:

 

"We are pleased to have signed our first licensing agreement with GHFG. CPH2's vision and values are closely aligned with our new partners, Alternus and Soleirtricity, and I am pleased to be able to share our innovative technology with them through our licence model. A core component of our business model is licensing out production to other companies, whilst also producing a certain number of units ourselves. By 2030, our goal is to produce approximately 1GW at CPH2 facilities and 3GW under licence. Our licensing model will help facilitate our growth strategy and accelerate market penetration to scale the business globally by providing a long-term revenue stream for CPH2, without the need for major upfront capex."

 

Eric Whelan, Chief Executive Officer of GHFG Ltd, , commented:

 

"Soleirtricity has a long-standing successful relationship with Alternus which has focused on the solar industry to date. Through this joint venture, GHFG will be responsible for the production of electrolysers to match the deployment of new Alternus solar projects where the addition of green hydrogen generation makes sense. It will also provide more direct control over the supply chain. Green hydrogen installations will allow Alternus to diversify into additional revenue streams from its growing market penetration in key markets across Europe and beyond.  It will also best exploit entry to another large and critical market in clean energy. Energy produced from the Alternus solar assets will be optimised to produce 100% green hydrogen, which is a critical component in the decarbonisation of transport and heavy industry. We look forward to broadening our contribution to a net zero future with all parties involved in this exciting new partnership".

 

For more information, please contact:

 

Clean Power Hydrogen Plc

via Camarco

Jon Duffy, Chief Executive Officer




Cenkos Securities plc - NOMAD & Broker


Neil McDonald

+44 (0)131 220 9771

Peter Lynch

+44 (0)131 220 9772

Adam Rae

+44 (0)131 220 9778



Camarco PR

+ 44(0) 20 3 757 4980

Billy Clegg


Owen Roberts


Lily Pettifar


 

To find out more, please visit: https://www.cph2.com

 

Overview of CPH2

CPH2 is the holding company of Clean Power Hydrogen Group Limited ("Clean Power") which has almost a decade of dedicated research and product development experience. This experience has resulted in the creation of simple, safe and sustainable technology which is designed to deliver a modular solution to the hydrogen production market in a cost-effective, scalable, reliable and long-lasting manner. The Group's strategic objective is to deliver the lowest LCOH in the market in relation to the production of green hydrogen. The Group's MFE technology is already commercially available and demonstrating cost efficiencies and technological advantages. CPH2 is listed on the AIM market and trades under the ticker LON:CPH2.

 

Overview of GHFG Ltd

Founded by entrepreneur Eric Whelan, GHFG Ltd. ("GHFG") produces green hydrogen through electrolysers co-located with renewable energy assets. Now a subsidiary of Alternus Energy Group Plc, GHFG can install electrolysers alongside select Alternus' solar PV projects internationally.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRSFSSMUEESELW

Last news